The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression.

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar ...

The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical company Johnson & Johnson created the spray from esketamine, a more ...

The Food and Drug Administration (FDA) recently expanded approval for Spravato, an antidepressant nasal spray used to treat depression. Parkside Psychiatric Hospital has a Spravato outpatient ...

A study led by researchers at Mass General Brigham suggests a nasal spray developed to target neuroinflammation could one day ...

J&J made it into a nasal spray to get it into the brain quickly ... about the risk of sedation and dissociation, respiratory depression, suicidal thoughts and abuse or misuse of the drug, among ...

A treatment tested by researchers in Boston found it improves motor function, coordination and spatial memory in mice. But it ...

Ketamine has been used as an anesthetic before surgeries for decades, but it can also be an option for those struggling with depression and suicidal thoughts- especially when anti-depressants and talk ...